Objective: This study aims to appraise 2017 AACE Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease by using Appraisal of Guidelines for Research and Evaluation II (AGREE II) tool. Method: A total of seven investigators who have obtained a postgraduate Doctor of Pharmacy or Masters of Clinical Pharmacy, appraised the dyslipidaemia guidelines independently, by using AGREE II tool. Key findings: Among all the domains, the highest-scoring domain was the clarity of presentation (87%), and the lowest was the applicability (26%). The assessors gave the top ranking for both ‘scope and purpose’ (78%) and ‘Editorial independence’ (79%). The overall guideline assessment was 61%. Most of the investigators (four out of s...
Guideline recommendations for the management of dyslipidemia, based on current trial evidence and/or...
Dyslipidaemia plays a major role in the pathogenesis of atherosclerosis. Every year, scientific inst...
Cardiovascular disease (CVD) is the leading cause of death and disability worldwide. CVD primary pre...
Background information: Dyslipidaemia, the unbalanced level of lipoproteins and triglycerides, contr...
Modern medicine is characterized by a continuous genesis of evidence making it very difficult to t...
Introduction: Cardiovascular diseases (CVDs) are one of the leading causes of morbidity and mortalit...
Objective: To appraise guidelines on cardiovascular risk assessment to guide selection of screening ...
Purpose of review: This review aims to identify common features of guidelines by comparing and summa...
Objectives To evaluate the methodological quality of the Palestinian Clinical Practice Guideline for...
After much anticipation, new dyslipidemia guidelines have been published by the American College of ...
Dyslipidemia is a major independent risk factor for the development of coronary heart disease, the c...
SummaryBackgroundScreening for and management of dyslipidaemia are crucial in primary and secondary ...
Even with the improvement in lifestyle interventions, a better control of cardiovascular (CV) risk f...
Dyslipidaemia plays a major role in the pathogenesis of atherosclerosis. Every year, scientific inst...
Background: The CArdiac MARker Guidelines Uptake in Europe Study (CAMARGUE) initiated by the Europea...
Guideline recommendations for the management of dyslipidemia, based on current trial evidence and/or...
Dyslipidaemia plays a major role in the pathogenesis of atherosclerosis. Every year, scientific inst...
Cardiovascular disease (CVD) is the leading cause of death and disability worldwide. CVD primary pre...
Background information: Dyslipidaemia, the unbalanced level of lipoproteins and triglycerides, contr...
Modern medicine is characterized by a continuous genesis of evidence making it very difficult to t...
Introduction: Cardiovascular diseases (CVDs) are one of the leading causes of morbidity and mortalit...
Objective: To appraise guidelines on cardiovascular risk assessment to guide selection of screening ...
Purpose of review: This review aims to identify common features of guidelines by comparing and summa...
Objectives To evaluate the methodological quality of the Palestinian Clinical Practice Guideline for...
After much anticipation, new dyslipidemia guidelines have been published by the American College of ...
Dyslipidemia is a major independent risk factor for the development of coronary heart disease, the c...
SummaryBackgroundScreening for and management of dyslipidaemia are crucial in primary and secondary ...
Even with the improvement in lifestyle interventions, a better control of cardiovascular (CV) risk f...
Dyslipidaemia plays a major role in the pathogenesis of atherosclerosis. Every year, scientific inst...
Background: The CArdiac MARker Guidelines Uptake in Europe Study (CAMARGUE) initiated by the Europea...
Guideline recommendations for the management of dyslipidemia, based on current trial evidence and/or...
Dyslipidaemia plays a major role in the pathogenesis of atherosclerosis. Every year, scientific inst...
Cardiovascular disease (CVD) is the leading cause of death and disability worldwide. CVD primary pre...